Table 2.

Perioperative and postoperative data of the patient cohort.

Variable	Cohort (n = 12)
Docking Time (min, median, IQR)	5.5 (4–6)
Console Time (min, median, IQR)	79.5 (58–91)
Estimated blood loss (mL, median, IQR)	200 (100–500)
Perioperative complications (n, %)	2 (16.70%)
Length of stay (days, median, IQR)	4 (3–5)
Hemoglobin at discharge (g/dL, median, IQR)	11 (8.90–11.90)
Creatinine at discharge (mg/dL, median, IQR)	0.91 (0.82–1.12)
eGFR at discharge (mL/min/1.73 m2, median, IQR)	67.9 (63.50–69.60)
Clavien Dindo Complications (n, %) - I - II - III - IV	0 (0%) 2 (16.70%), fever 0 (0%) 0 (0%)
Pathological Size (mm, median, IQR)	41.5 (25–55)
Histology_subtype (n, %) - Cystic Clear Cell RCC - Cystic Papillary RCC	6 (50%) 6 (50%)
Positive Margins (n, %)	1 (8.40%)
pT Stage (n, %) - 1a - 1b - 2a - 2b - 3a	6 (50%) 2 (16.70%) 2 (16.70%) 1 (8.40%) 1 (8.40%)
Last follow-up (months, median, IQR)	10 (3–12)
Hemoglobin at 1 month (g/dL, median, IQR)	12 (10–14)
Creatinine at 1 month (mg/dL, median, IQR)	0.93 (0.86–0.97)
eGFR at 1 month (mL/min/1.73 m2, median, IQR)	79.9 (66.20–86.90)
Hemoglobin at the last follow-up (g/dL, median, IQR)	13 (11–14)
Creatinine at the last follow-up (mg/dL, median, IQR)	0.86 (0.83–1.03)
eGFR at the last follow-up (mL/min/1.73 m2, median, IQR)	80.1 (70.40–86.90)
Trifecta achievement rate (n, %)	11 (91.70%)

eGFR: estimated glomerular filtration rate.